Skip to Main Content

Author Details

Anne-Lise B??rresen-Dale
Institute for Cancer Research, Oslo University Hospital
1972
579
102
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36968142A <i>PRRX1</i> Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.Cancer Res Commun2023
36968142A <i>PRRX1</i> Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.Cancer Res Commun2023
36477895Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers.Nucleic Acids Res2022
36477895Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers.Nucleic Acids Res2022
33176066High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.Mol Oncol2021
33471991Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.N Engl J Med2021
34036235Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.JCO Precis Oncol2021
33176066High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.Mol Oncol2021
34737229Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation.Proc Natl Acad Sci U S A2021
34508103Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3<sup>VNTR</sup> polymorphisms and gene co-expression.NPJ Breast Cancer2021
34737229Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation.Proc Natl Acad Sci U S A2021
34508103Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3<sup>VNTR</sup> polymorphisms and gene co-expression.NPJ Breast Cancer2021
34036235Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.JCO Precis Oncol2021
33471991Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.N Engl J Med2021
32488909Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.Int J Cancer2020
31949161A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.Nat Commun2020
32488909Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.Int J Cancer2020
32208873Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.Acta Oncol2020
31949161A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.Nat Commun2020
32208873Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.Acta Oncol2020
30692535Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.Nat Commun2019
31704995PathTracer: High-sensitivity detection of differential pathway activity in tumours.Sci Rep2019
30520388miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.Microrna2019
30692535Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.Nat Commun2019
30804006Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.Cancer Immunol Res2019
30962452Breast cancer quantitative proteome and proteogenomic landscape.Nat Commun2019
31402562miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.Mol Oncol2019
30990221TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.J Natl Cancer Inst2019
30988298Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation.Nat Commun2019
31704995PathTracer: High-sensitivity detection of differential pathway activity in tumours.Sci Rep2019
31402562miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.Mol Oncol2019
30990221TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.J Natl Cancer Inst2019
30988298Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation.Nat Commun2019
30804006Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.Cancer Immunol Res2019
30962452Breast cancer quantitative proteome and proteogenomic landscape.Nat Commun2019
30520388miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.Microrna2019
29338700Correction to: A systematic comparison of copy number alterations in four types of female cancer.BMC Cancer2018
29054988AKT1<sup>low</sup> Quiescent Cancer Cells Promote Solid Tumor Growth.Mol Cancer Ther2018
30559362Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.Nat Commun2018
30497530Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.Genome Med2018
30377556Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.Oncoimmunology2018
30133130Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.Mol Oncol2018
29338700Correction to: A systematic comparison of copy number alterations in four types of female cancer.BMC Cancer2018
29698574N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome.Mol Oncol2018
29741811Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4.Mol Oncol2018
29633761Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.Nat Commun2018
30713794Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics.Oncoimmunology2018
30133130Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.Mol Oncol2018
30713794Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics.Oncoimmunology2018
30377556Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.Oncoimmunology2018
  • 1 - 50 of 1,158

Recommended Authors

Teresa Ram??n y Cajal
Familial Cancer Clinic, Hospital Sant Pau
Career Start Year 2000
Number of shared co-authors 74
Dirce Maria Carraro
AC Camargo Cancer Center
Career Start Year 1998
Number of shared co-authors 10
Mar??a J Garc??a
Spanish National Cancer Research Centre (CNIO)
Career Start Year 1996
Number of shared co-authors 92
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 22
Anne-Marie Martin
Novartis Pharmaceuticals
Career Start Year 1995
Number of shared co-authors 5
Marbin Pineda
Center for Cancer Research, National Cancer Institute
Career Start Year 1995
Number of shared co-authors 25
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 2
Anamaria A Camargo
Hospital Sirio-Libanes
Career Start Year 1994
Number of shared co-authors 6
Aleksandra To??oczko-Grabarek
Pomeranian Medical University in Szczecin
Career Start Year 1994
Number of shared co-authors 91
Nalan Gokgoz
Lunenfeld-Tanenbaum Research Institute
Career Start Year 1993
Number of shared co-authors 35
Otavia L Caballero
Ludwig Institute for Cancer Research Ltd.
Career Start Year 1993
Number of shared co-authors 4
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 3
Yusuke Nakamura
Japanese Foundation for Cancer Research
Career Start Year 1992
Number of shared co-authors 65
Peggy L Porter
Fred Hutchinson Cancer Research Center
Career Start Year 1991
Number of shared co-authors 15
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 13
Eberhard Korsching
Institutet of Bioinformatics, University Hospital of Munster, University of Munster
Career Start Year 1990
Number of shared co-authors 1
Gregory J Tsongalis
Dartmouth Health and the Dartmouth Cancer Center, USA Geisel School of Medicine
Career Start Year 1990
Number of shared co-authors 4
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 15
Robyn L Ward
University of Sydney
Career Start Year 1989
Number of shared co-authors 30
Ming K Lee
University of Washington
Career Start Year 1988
Number of shared co-authors 6
Mark A Watson
Washington University School of Medicine
Career Start Year 1987
Number of shared co-authors 8
Brent W Zanke
University of Toronto
Career Start Year 1987
Number of shared co-authors 50
Silvano Bosari
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 2
Jos?? Palacios
Universidad de Alcala
Career Start Year 1983
Number of shared co-authors 58
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 15
Michael Dean
National Cancer Institute
Career Start Year 1980
Number of shared co-authors 61
Stephen N Thibodeau
Mayo Clinic
Career Start Year 1978
Number of shared co-authors 111
Mary-Claire King
University of Washington
Career Start Year 1975
Number of shared co-authors 26
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 71
Maria Mitzi Brentani
Sao Paulo University
Career Start Year 1964
Number of shared co-authors 0

Collaborators

Vessela N Kristensen
Faculty of Clinical Medicine, University of Oslo
Co-authored papers 164
Ole Christian Lingj??rde
University of Oslo
Co-authored papers 56
Jahn M Nesland
The Norwegian Radium Hospital, Oslo University Hospital
Co-authored papers 46
Douglas F Easton
University of Cambridge
Co-authored papers 44
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 42
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 40
Alison M Dunning
Co-authored papers 40
Fergus J Couch
Mayo Clinic
Co-authored papers 40
Per Hall
Co-authored papers 40
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 38
Graham G Giles
Co-authored papers 38
Irene L Andrulis
University of Toronto
Co-authored papers 37
Montserrat Garcia-Closas
National Cancer Institute
Co-authored papers 37
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 36
Hoda Anton-Culver
University of California irvine
Co-authored papers 35
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 34
Roger L Milne
Co-authored papers 33
Jonine D Figueroa
The Usher Institute, The University of Edinburgh
Co-authored papers 32
Diether Lambrechts
Co-authored papers 32
Christopher A Haiman
University of Southern California
Co-authored papers 31
Jan Lubinski
Pomeranian Medical University
Co-authored papers 31
Janet E Olson
Mayo Clinic
Co-authored papers 29
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 28
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Co-authored papers 28
Julia A Knight
Co-authored papers 26
Paolo Radice
Ospedale Circolo e Fondazione Macchi
Co-authored papers 26
Caroline Seynaeve
Erasmus Medical Center
Co-authored papers 25
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 24
Wei Zheng
Co-authored papers 24
Loic Le Marchand
Co-authored papers 24
Release 1.2